A pan‑cancer study from Weill Cornell Medicine, Illumina and NewYork‑Presbyterian used whole‑genome sequencing (WGS) and an Isabl‑derived classifier to detect homologous recombination deficiency (HRD) patterns missed by other assays across 453 patients. Investigators reported HRD detection rates of 21% in breast, 20% in pancreatic/bile duct, and 17% in gynecological cancers, among others, and argued WGS provides a comprehensive assessment of structural variants and copy number changes relevant to PARP inhibitor and platinum chemotherapy selection. The work was published in Communications Medicine.